The 5-HT2A receptor is one of the most important serotonin receptors, serving as major targets for risperidone, an atypical antipsychotic increasingly used for treatment of many psychotic disorders.The rs6311 and rs6313 polymorphisms in HTR2A gene have been reported to be associated with response to rispeddone treatment.But many previous studies yielded conflicting results.To confirm the importance of these polymorphisms in risperidone treatment and provide more evidences for the routine use of these pharmacogenetic biomarkers in clinical practice, we carried out an association analysis of rs6311 and rs6313 polymorphisms with risperidone efficacy in Chinese Han patients with schizophrenia.Two independent cohorts of unrelated subjects were recruited from Henan and Shanghai (95 and 113 subjects, respectively).After a 4-week or 8-week risperidone monotherapy, rs6311 and rs6313 polymorphisms of these subjects were genotyped with MassARRAY.And clinical improvement was measured by the reduction of PANSS scores (including the total and subscale sores).As in previous studies, rs6311G allele was in complete linkage disequilibrium with rs6313C allele.UNIANOVA and case-control study was used to evaluate the effects of rs6311 and rs6313 polymorphisms on risperidone efficacy.But no significant association was found.The relative large sample size and 2 independent cohorts of subjects would enhance the reliability of our findings.But they still should be treated with caution, due to the limited genetic and nog-genetic factors taken into consideration.And more comprehensive replication studies with larger sample size are still in need.